We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+11.19%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$510M
AUM Growth
+$94.9M
Cap. Flow
+$120M
Cap. Flow %
23.47%
Top 10 Hldgs %
49.51%
Holding
57
New
17
Increased
16
Reduced
7
Closed
15

Top Buys

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$22.4M
2
OPTN
OptiNose
OPTN
+$20M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.6M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$17.1M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$13.5M

Top Sells

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$18.9M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$13.1M
3
ALKS icon
Alkermes
ALKS
+$11M
4
BBIO icon
BridgeBio Pharma
BBIO
+$10.4M
5
TVTX icon
Travere Therapeutics
TVTX
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
26
Amylyx Pharmaceuticals
AMLX
$2.26B
$7.02M 1.38%
+190,000
New +$6.74M
MLTX icon
27
MoonLake Immunotherapeutics
MLTX
$1.57B
$6.75M 1.32%
642,566
+150,566
+31% +$1.34M
ERAS icon
28
Erasca
ERAS
$6.3B
$6.63M 1.3%
+1,538,461
New +$10.4M
ICPT
29
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$6.54M 1.28%
528,850
+423,850
+404% +$6M
ABOS icon
30
Acumen Pharmaceuticals
ABOS
$155M
$6.03M 1.18%
1,116,581
-83,419
-7% -$561K
MRTX
31
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.03M 1.18%
+133,000
New +$8.61M
VERV
32
DELISTED
Verve Therapeutics
VERV
$5.8M 1.14%
+300,000
New +$7.95M
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
$5.78M 1.13%
+267,283
New +$5.65M
LRMR icon
34
Larimar Therapeutics
LRMR
$397M
$5.26M 1.03%
1,273,635
+138,635
+12% +$473K
URGN icon
35
UroGen Pharma
URGN
$1.86B
$4.97M 0.97%
560,000
-313,424
-36% -$2.97M
DTIL icon
36
Precision BioSciences
DTIL
$180M
$4.52M 0.89%
126,710
+36,350
+40% +$1.44M
GRCL
37
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$4.51M 0.88%
1,962,399
+1,513,350
+337% +$4.64M
GBIO
38
DELISTED
Generation Bio
GBIO
$4.02M 0.79%
102,254
+19,746
+24% +$1.04M
EOLS icon
39
Evolus
EOLS
$385M
$1.43M 0.28%
+190,329
New +$1.47M
ALKS icon
40
Alkermes
ALKS
$8.22B
$1.21M 0.24%
46,185
-461,315
-91% -$11M
IMUX icon
41
Immunic
IMUX
$190M
$885K 0.17%
+63,218
New +$1.72M
ANAB icon
42
AnaptysBio
ANAB
$1.58B
$465K 0.09%
+15,000
New +$424K
BBIO icon
43
BridgeBio Pharma
BBIO
$15.7B
– –
-1,050,000
Closed -$10.4M
DNTH icon
44
Dianthus Therapeutics
DNTH
$5.84B
– –
-63,693
Closed -$1.44M
ETNB
45
DELISTED
89bio
ETNB
– –
-955,000
Closed -$5.53M
LKFT
46
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
– –
-306,411
Closed -$13.1M
IMCR icon
47
Immunocore
IMCR
$1.72B
– –
-78,527
Closed -$3.69M
MDGL icon
48
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-95,500
Closed -$6.21M
MIST icon
49
Milestone Pharmaceuticals
MIST
$138M
– –
-674,656
Closed -$6.2M
NKTR icon
50
Nektar Therapeutics
NKTR
$2.39B
– –
-29,855
Closed -$1.43M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Great Point Partners held 57 positions worth $510M, up 23% from $415M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Great Point Partners deployed $120M of net new capital in Q4 2022, opening 17 new positions and adding to 16 existing holdings. Its largest new stake was OptiNose: 526,316 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Alkermes, an estimated $11M trimmed.

  • Great Point Partners's largest Q4 2022 buy was OptiNose: 526,316 shares worth $14.6M.
  • Great Point Partners added most to RAPT Therapeutics in Q4 2022, an estimated $22.4M increase.
  • Great Point Partners's biggest Q4 2022 reduction was Alkermes, cutting an estimated $11M.
  • Great Point Partners fully exited Relmada Therapeutics in Q4 2022, selling an estimated $18.9M.
  • Great Point Partners's ten largest holdings make up 50% of its $510M portfolio in Q4 2022.
  • Great Point Partners opened 17 new positions and closed 15 in Q4 2022.
  • Great Point Partners's portfolio value rose 23% quarter-over-quarter to $510M.

Based on Great Point Partners's 13F filing for Q4 2022, filed 14 Feb 2023.